Market Cap 67.39M
Revenue (ttm) 0.00
Net Income (ttm) -9.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 31,700
Avg Vol 80,670
Day's Range N/A - N/A
Shares Out 4.52M
Stochastic %K 43%
Beta 0.33
Analysts Sell
Price Target $39.00

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilim...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 994 8250
Address:
149 Fifth Avenue, Suite 500, New York, United States
Dancady1
Dancady1 Oct. 6 at 8:28 PM
0 · Reply
sidewayzonly
sidewayzonly Oct. 5 at 7:50 AM
$INKT Technology services growth. Testing resistance level. Volume expansion needed for continuation. Sector momentum building.
0 · Reply
FreeWhales
FreeWhales Oct. 3 at 2:28 AM
0 · Reply
Biotechguy21
Biotechguy21 Oct. 2 at 12:43 AM
$INKT $AGEN checking on my favorite two pos of stocks and nothing surprising . Both down. 🤡🤡😂😂
0 · Reply
2_logs_higher
2_logs_higher Sep. 29 at 2:16 PM
$AGEN & $INKT new bod for mink https://investor.minktherapeutics.com/node/8271/pdf
0 · Reply
LegendaryCharts
LegendaryCharts Sep. 28 at 10:20 PM
$PAVS Bullish momentum breakout on this tiny float! top watch tomorrow premarket! $BLUE News due soon $EKLB top swing $INKT due for a pop soon
0 · Reply
neversurrender2024
neversurrender2024 Sep. 26 at 12:04 PM
$INKT whats the odds that garos dumping shares here to keep the lights on over at $AGEN...ITS going lower here as well folks....stay tuned!
0 · Reply
2_logs_higher
2_logs_higher Sep. 25 at 1:13 PM
$AGEN & $INKT
0 · Reply
enkemm
enkemm Sep. 24 at 4:10 AM
$INKT Neversurrender>>>>>>>>>you are big time hater...so why post? Does it somehow satiate the emptiness that hate creates in one's soul? Perhaps this prediction will spark your IRE>>>by the end of this year, INKT will be at $30.00/share. Of course, you would almost certainly rather have a sharp stick in the eye, eh?
0 · Reply
neversurrender2024
neversurrender2024 Sep. 23 at 12:12 PM
$INKT $180 a share a few years back, management like $AGEN is terrible here folks!
1 · Reply
Latest News on INKT
MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:15 PM EDT - 7 weeks ago

MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript


MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:33 PM EDT - 4 months ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting


MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript

May 15, 2025, 1:21 PM EDT - 5 months ago

MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript


MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 11:28 AM EDT - 7 months ago

MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript


MiNK Reports Second Quarter 2024 Results and Business Update

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Second Quarter 2024 Results and Business Update


MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript

May 14, 2024, 11:07 AM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript


MiNK Reports First Quarter 2024 Results

May 14, 2024, 7:30 AM EDT - 1 year ago

MiNK Reports First Quarter 2024 Results


MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 21, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Fourth Quarter and Year-End 2023 Results


MiNK Therapeutics Reports Third Quarter 2023 Results

Nov 9, 2023, 7:00 AM EST - 2 years ago

MiNK Therapeutics Reports Third Quarter 2023 Results


MiNK Therapeutics Reports Second Quarter 2023 Results

Aug 10, 2023, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Reports Second Quarter 2023 Results


Dancady1
Dancady1 Oct. 6 at 8:28 PM
0 · Reply
sidewayzonly
sidewayzonly Oct. 5 at 7:50 AM
$INKT Technology services growth. Testing resistance level. Volume expansion needed for continuation. Sector momentum building.
0 · Reply
FreeWhales
FreeWhales Oct. 3 at 2:28 AM
0 · Reply
Biotechguy21
Biotechguy21 Oct. 2 at 12:43 AM
$INKT $AGEN checking on my favorite two pos of stocks and nothing surprising . Both down. 🤡🤡😂😂
0 · Reply
2_logs_higher
2_logs_higher Sep. 29 at 2:16 PM
$AGEN & $INKT new bod for mink https://investor.minktherapeutics.com/node/8271/pdf
0 · Reply
LegendaryCharts
LegendaryCharts Sep. 28 at 10:20 PM
$PAVS Bullish momentum breakout on this tiny float! top watch tomorrow premarket! $BLUE News due soon $EKLB top swing $INKT due for a pop soon
0 · Reply
neversurrender2024
neversurrender2024 Sep. 26 at 12:04 PM
$INKT whats the odds that garos dumping shares here to keep the lights on over at $AGEN...ITS going lower here as well folks....stay tuned!
0 · Reply
2_logs_higher
2_logs_higher Sep. 25 at 1:13 PM
$AGEN & $INKT
0 · Reply
enkemm
enkemm Sep. 24 at 4:10 AM
$INKT Neversurrender>>>>>>>>>you are big time hater...so why post? Does it somehow satiate the emptiness that hate creates in one's soul? Perhaps this prediction will spark your IRE>>>by the end of this year, INKT will be at $30.00/share. Of course, you would almost certainly rather have a sharp stick in the eye, eh?
0 · Reply
neversurrender2024
neversurrender2024 Sep. 23 at 12:12 PM
$INKT $180 a share a few years back, management like $AGEN is terrible here folks!
1 · Reply
Ron_Burn
Ron_Burn Sep. 23 at 2:03 AM
$INKT getting reay
0 · Reply
Tigertkbc
Tigertkbc Sep. 22 at 7:07 PM
$INKT One of these days!
0 · Reply
2_logs_higher
2_logs_higher Sep. 20 at 11:19 AM
$AGEN & $INKT
1 · Reply
Biotechguy21
Biotechguy21 Sep. 20 at 2:17 AM
$INKT $AGEN two huge pos stocks. same team. Same dilution. 😂😂🤡🤡👀👀
0 · Reply
Tigertkbc
Tigertkbc Sep. 19 at 11:03 PM
$INKT One of these days!
0 · Reply
2_logs_higher
2_logs_higher Sep. 18 at 5:48 PM
$AGEN & $INKT hiring as well
4 · Reply
enkemm
enkemm Sep. 18 at 1:09 PM
$INKT Dr. Terese Hammond has joined the team as Head of Inflammatory and Pulmonary Diseases, effective immediately. This is a very, very good look. Me thinks she would not jump aboard unless imminent substantive goodness was within her grasp.
0 · Reply
Novaful
Novaful Sep. 18 at 11:59 AM
$INKT MiNK Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in invariant natural killer T (iNKT) cell therapies, has announced the imminent launch of a grant-funded clinical trial targeting graft-versus-host disease (GVHD). Additionally, the company is advancing its clinical program in severe pulmonary inflammatory disease. These initiatives are part of MiNK's strategy to prioritize substantial, low-risk opportunities backed by strong biologic rationale and peer-reviewed data. The company has appointed Dr. Terese C. Hammond as Head of Inflammatory and Pulmonary Diseases to lead these efforts. Dr. Hammond will draw upon her clinical experience to enhance trial execution and study design. Results from these trials have not yet been presented.
0 · Reply
BrettStocks
BrettStocks Sep. 11 at 11:15 AM
$SLXN Getting possible $INKT vibes
0 · Reply
Dancady1
Dancady1 Sep. 10 at 4:12 PM
$INKT pos
1 · Reply
Novaful
Novaful Sep. 10 at 12:01 PM
$INKT next good PR we will see 30
0 · Reply
Dgun
Dgun Sep. 9 at 7:37 PM
0 · Reply